Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Apogee Therapeutics, Inc. Common Stock (APGE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: APGE (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 65.25% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.31B USD | Price to earnings Ratio - | 1Y Target Price 93.88 |
Price to earnings Ratio - | 1Y Target Price 93.88 | ||
Volume (30-day avg) 750994 | Beta - | 52 Weeks Range 29.10 - 63.50 | Updated Date 04/1/2025 |
52 Weeks Range 29.10 - 63.50 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.3 |
Earnings Date
Report Date 2025-03-11 | When - | Estimate -1.0725 | Actual -1.2 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.46% | Return on Equity (TTM) -33.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1661321657 | Price to Sales(TTM) - |
Enterprise Value 1661321657 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 44600700 | Shares Floating 39037608 |
Shares Outstanding 44600700 | Shares Floating 39037608 | ||
Percent Insiders 11.37 | Percent Institutions 130.16 |
Analyst Ratings
Rating 5 | Target Price 92.29 | Buy - | Strong Buy 8 |
Buy - | Strong Buy 8 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Apogee Therapeutics, Inc. Common Stock
Company Overview
History and Background
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel biologics for the treatment of inflammatory and immunologic diseases. Founded in 2022, the company is relatively new and rapidly advancing its pipeline of potential therapies.
Core Business Areas
- IgE Pathway Targeting: Developing therapies targeting the IgE pathway for atopic dermatitis and other allergic diseases.
- IL-13 Pathway Targeting: Developing therapies targeting IL-13 for inflammatory diseases.
- Pipeline Expansion: Exploring new targets and indications in immunology.
Leadership and Structure
The leadership team comprises experienced biotech executives and scientists. Details of the organizational structure are typically found in SEC filings and investor presentations.
Top Products and Market Share
Key Offerings
- APG777: A lead candidate targeting IL-13 for atopic dermatitis. Phase 1 studies have been completed, with further clinical development underway. Competitors include Sanofi/Regeneron (Dupixent).
- APG808: An anti-IL-4Ru03b1 antibody, being developed for atopic dermatitis and asthma. Competitors include Sanofi/Regeneron (Dupixent).
Market Dynamics
Industry Overview
The biopharmaceutical industry is competitive, with significant unmet needs in inflammatory and immunologic diseases. Development and regulatory pathways are rigorous and costly.
Positioning
Apogee is positioning itself as a leader in developing novel biologics for inflammatory and immunologic diseases, focusing on differentiated product profiles and improved patient outcomes. Their competitive advantage is a strong antibody engineering and development platform.
Total Addressable Market (TAM)
The TAM for atopic dermatitis and other allergic and inflammatory diseases is estimated to be tens of billions of dollars. Apogee is aiming to capture a significant share through superior efficacy, safety, and convenience compared to existing therapies.
Upturn SWOT Analysis
Strengths
- Novel biologics pipeline
- Experienced leadership team
- Strong intellectual property position
- Promising early clinical data
Weaknesses
- Early-stage company
- High cash burn rate
- Reliance on clinical trial success
- Competition from established players
Opportunities
- Expanding pipeline to new indications
- Partnering with larger pharmaceutical companies
- Achieving breakthrough therapy designation
- Addressing unmet needs in specific patient populations
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing and emerging therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- SNY (Sanofi)
- REGN (Regeneron)
- BMY (Bristol-Myers Squibb)
- LLY (Eli Lilly)
Competitive Landscape
Apogee competes with established pharmaceutical companies and other biotech firms in the development of therapies for inflammatory and immunologic diseases. Its competitive advantage lies in its novel biologics and differentiated product profiles.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the advancement of its pipeline and fundraising success since its founding.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and commercialization of its products. Analyst estimates vary but generally project significant revenue potential if products reach the market.
Recent Initiatives: Recent initiatives include advancing its lead candidate APG777 into further clinical development and expanding its pipeline with new targets.
Summary
Apogee Therapeutics is a promising clinical-stage biotech company with a focus on inflammatory and immunologic diseases. Its strong pipeline and experienced leadership are positives. However, it faces the challenges of clinical trial success, regulatory hurdles, and competition from larger players. Its future depends on effectively navigating these challenges and bringing its novel therapies to market.
Similar Companies
- SNY
- REGN
- XBI
- LABU
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biopharmaceutical industry is inherently risky, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Apogee Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2023-07-14 | CEO & Director Dr. Michael Thomas Henderson M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 196 | |
Full time employees 196 | |||
Apogee Therapeutics, Inc., a clinical stage biotechnology company, advances novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD which is in phase 2; for the treatment of asthma and EoE which is in phase 1. It also develops APG279 which is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra, for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.